Hema-Plus Indications/Uses

Treatment of anemia due to chronic renal disease: Hema-Plus is indicated for the treatment of anemia associated to chronic renal failure, including both, dialysis patients and predialysis patients. The product is indicated to elevate or maintain the red blood cell level as manifested by the hematocrit or hemoglobin determinations and to decrease the need for transfusions in these patients.
Prior to initiation of therapy the patient's iron stores, including transferrin saturation and ferritin, which should be at least 20% and 100 ng/mL, respectively, should be evaluated. Blood pressure has to be properly controlled and monitored very carefully during the treatment. The treatment should be considered in patients with a hematocrit less than 30%.
Treatment of cancer patients on chemotherapy: Hema-Plus is indicated for anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy for at least two months, and its purpose is to increase or preserve the level of erythrocytes in blood, shown or expressed through the hematocrit or hemoglobin level, and therefore reduce the number of transfusions these patients need.